KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other financing activities (2020 - 2025)

Historic Other financing activities for Esperion Therapeutics (ESPR) over the last 6 years, with Q1 2025 value amounting to $7.5 million.

  • Esperion Therapeutics' Other financing activities changed N/A to $7.5 million in Q1 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 12173.73%. This contributed to the annual value of $29000.0 for FY2024, which is 3809.52% up from last year.
  • Esperion Therapeutics' Other financing activities amounted to $7.5 million in Q1 2025.
  • Esperion Therapeutics' 5-year Other financing activities high stood at $9.6 million for Q3 2024, and its period low was -$9.6 million during Q4 2024.
  • For the 5-year period, Esperion Therapeutics' Other financing activities averaged around $971375.0, with its median value being $134500.0 (2021).
  • Per our database at Business Quant, Esperion Therapeutics' Other financing activities skyrocketed by 33800.0% in 2022 and then tumbled by 4580000.0% in 2024.
  • Esperion Therapeutics' Other financing activities (Quarter) stood at $390000.0 in 2021, then crashed by 212.31% to -$438000.0 in 2022, then surged by 104.79% to $21000.0 in 2023, then tumbled by 45800.0% to -$9.6 million in 2024, then skyrocketed by 178.15% to $7.5 million in 2025.
  • Its Other financing activities was $7.5 million in Q1 2025, compared to -$9.6 million in Q4 2024 and $9.6 million in Q3 2024.